Oppenheimer Reiterates Outperform Rating, $10 PT on BioLineRx (BLRX)
Tweet Send to a Friend
Oppenheimer analyst Mark Breindenbach reiterated an Outperform rating and $10.00 price target on BioLineRx ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
